After Dropping 94% From Post IPO high from $19.45, a loss of exceeding $3 billion and change, ATAI is in the early stages of a recovery (our opinion) gaining 94%...
Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine
LIVE QUOTE
Bargain Hunters Dream
View Post
ENGLEWOOD CLIFFS, NJ, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with...
We watched an excellent presentation from management at the Dawson conference and starting our due diligence now. Primary item of our interest is a joint...
Thus, to us, the key potential positive events that could lead to a rerating in PHRM.CN shares include publication of the Phase 2 trial data evaluating ketamine in LID-PD in...
MIAMI, June 03, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today its KetaDASH subsidiary will accept delivery of...
